FORM 1449* INFORMATION DISCLOSURE STATEMENT	Docket Number: 09424.0238USWO	Application Number: 10/581,611
IN AN APPLICATION	Applicant: BERNS et al.	
(Use several sheets if necessary)	Filing Date: June 5, 2006	Group Art Unit: Unknown

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES	TRANSLATION NO
	WO/02068579	09/06/2002	WIPO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		Almere, Sept. 2000, *The Netherlands: Excerpta Medica*, p. 116-7 "XI.04 Definitions of objective response"
		Brown et al., Jan. 1999, *Nat. Genet.*, 21:33-7 "Exploring the new world of genome with DNA microarrays"
		Charpentier et al., Nov. 2000, *Cancer Res.*, 60:5977-83 "Effects of Estrogen on Global Gene Expression: Identification of Novel Targets of Estrogen Action"
		Ding et al., Sept. 2004, *Br. J. Cancer*, 90:1995-2001 "Abnormality of the DNA double-strand-break checkpoint/repair genes, *ATM, BRCA1* and *TP53*, in breast cancer is related to tumour grade"

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.

FORM 1449*		Docket Number:	Application Number:
INFORMATION DISCLOSURE STATEMENT		09424.0238USWO	10/581,611
IN AN APPLICATION		Applicant: BERNS et al.	
(Use several sheets if necessary)		Filing Date: June 5, 2006	Group Art Unit: Unknown

		Dowsett, 2004, *Breast Cancer Research and Treatment*, 87:1, pp. S11-S18 "Biomarker investigations from the ATAC trial: the role of TA01"
		Ferrero-Pous et al., Dec. 2000, *Clin. Cancer Res.*, 6:4745-54 "Relationship between c-*erb*B-2 and Other Tumor Characteristics in Breast Cancer Prognosis"
		Foekens et al., 1994, *Br. J. Cancer*, 70:1217-23 "Relationship of PS2 with response to tamoxifen therapy in patients with recurrent breast cancer"
		Foekens et al., July 2001, *Cancer Res.*, 61:5407-14 "High Tumor Levels of Vascular Endothelial Growth Factor Predict Poor Response to Systemic Therapy in Advanced Breast Cancer"
		Frasor et al., Oct. 2003, *Endocrinology*, 144:4562-74 "Profiling of Estrogen Up- and Down-Regulated Gene Expression in Human Breast Cancer Cells: Insights into Gene Networks and Pathways Underlying Estrogenic Control of Proliferation and Cell Phenotype"
		GenBank GEO, 11 March 2002, XP002293987 (Abstract) "Affymetrix GeneChip Human Genome U95 Set HG-U95A"
		Gruvberger et al., Aug. 2001, *Cancer Res.*, 61:5979-84 "Estrogen Receptor Status in Breast Cancer Is Associated with Remarkably Distinct Gene Expression Patterns"
		Hayward et al., Mar. 1977, *Cancer*, 39:1289-94 "Assessment of Response to Therapy in Advanced Breast Cancer"
		Holloway, et al., 2002, *Gynecol. Oncol.*, 87:8-16 "Association between *in Vitro* Platinum Resistance in the EDR Assay and Clinical Outcomes for Ovarian Cancer Patients"
		Hyman et al., Nov. 2002, *Cancer Res.*, 62:6240-5 "Impact of DNA Amplification on Gene Expression Patterns in Breast Cancer"
		Iacobuzio-Donahue, et al., Sept. 2002, *Cancer Res.*, 62:5351-7 "The Desmoplastic Response to Infiltrating Breast Carcinoma: Gene Expression at the Site of Primary Invasion and Implications for Comparisons between Tumor Types"
		Jansen et al., 2003, *Breast Cancer Research and Treatment*, 82:1 p. S14 "Molecular classification of tamoxifen-responsive and -resistant breast carcinomas by gene expression profiling."
		Jansen et al., Feb. 2005, *J. of Clin. Oncology*, 23(4):732-740 "Molecular Classification of Tamoxifen-Resistant Breast Carcinomas by Gene Expression Profiling"
		Jones et al., May 2004, *Cancer Res.*, 64:3037-3045 "Expression Profiling of Purified Normal Human Luminal and Myoepithelial Breast Cells: Identification of Novel Prognostic Markers for Breast Cancer"

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.

FORM 1449*		Docket Number:	Application Number:
INFORMATION DISCLOSURE STATEMENT		09424.0238USWO	10/581,611
IN AN APPLICATION		Applicant: BERNS et al.	
(Use several sheets if necessary)		Filing Date: June 5, 2006	Group Art Unit: Unknown

		Jordan, Mar. 2003, *Nt. Rev. Drug Discov.*, 2:205:-13 "Tamoxifen: A Most Unlikely Pioneering Medicine"
		Kaplan and Meier, 1958, *J. Am. Assoc.*, 53:457-481 "Nonparametric Estimation From Incomplete Observations"
		Klijn et al., 2002, Ingle WRMaJN (ed): *Endocrine Therapy in Breast Cancer*, NNY Marcel Dekker "Other Endocrine and Biological Agents in the Treatment of Advanced Breast Cancer"
		Lipton et al., May 2003, *J. Clin. Oncol.*, 21(10):1967-72 "Serum *HER-2/neu* and Response to the Aromatase Inhibitor Letrozole Versus Tamoxifen"
		Los et al., 2002, *Cytometry*, 47:66-71 "Using mRNA Expression Profiling to Determine Anticancer Drug Efficacy"
		Ma et al., June 2004, *Cancer Cell*, 5(6):607-16 "A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen"
		Mackay et al., 2003, *Oncogene*, 22:2680-8 "cDNA microarray analysis of genes associated with *ERBB2* (HER2/neu) overexpression in human mammary luminal epithelial cells"
		Mandlekar et al., 2001, *Apoptosis*, 6(6):469-77 "Mechanisms of tamoxifen-induced apoptosis"
		Martens et al., 2003, *Thromb. Haemost.*, 89:393-404 "Aging of stromal-derived human breast fibroblasts might contribute to breast cancer progression"
		Osborne, Nov. 1998, *N. Engl. J. Med.*, 339(22):1609-18 "Tamoxifen in the Treatment of Breast Cancer"
		Osborne, July 2000, *Cancer Res.*, 60:3706-12 "A Genome-wide Map Showing Common Regions of Loss of Heterozygosity/Allelic Imbalance in Breast Cancer"
		Paik et al., 2003, *Breast Cancer Res. Treat.*, 82:S10 "Multi-gene RT-PCR assay for predicting recurrence in node negative breast cancer patients—NSABP studies B-20 and B-14."
		Pusztai et al., July 2003, *Clin. Cancer Res.*, 9:2406-15 "Gene Expression Profiles Obtained from Fine-Needle Aspirations of Breast Cancer Reliably Identify Routine Prognostic Markers and Reveal Large-Scale Molecular Differences between Estrogen-negative and Estrogen-positive Tumors"
		Ravdin et al., Aug. 1992, *J. Clin. Oncol.*, 10(8):1284-91 "Prognostic Significance of Progesterone Receptor Levels in Estrogen Receptor-Positive Patients With Tamoxifen: Results of a Prospective Southwest Oncology Group Study"

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.

FORM 1449* **INFORMATION DISCLOSURE STATEMENT** **IN AN APPLICATION** (Use several sheets if necessary)	Docket Number: 09424.0238USWO	Application Number: 10/581,611
	Applicant: BERNS et al.	
	Filing Date: June 5, 2006	Group Art Unit: Unknown

		Robertson et al., 1997, *Eur. J. Cancer,* 33(11):1774-9 "The Clinical Relevance of Static Disease (No Change) Category for 6 Months on Endocrine Therapy in Patients with Breast Cancer"
		Sreekumar et al., Dec. 2002, Biotechniques Eaton Publishing, Natick US pp. 46-53 Using Protein Microarrays to Study Cancer"
		Tang et al., 2004, *Nucleic Acids Res.,* 32 Database issue:D533-6 "ERGDB: Estrogen Responsive Genes Database"
		van't Veer et al., Jan. 2002, *Nature,* 415:530-6 "Gene expression profiling predicts clinical outcome of breast cancer"
		Weigelt et al., Dec. 2003, *Proc. Natl. Acad. Sci., U.S.A.,* 100(26):15901-5 "Gene expression profiles of primary breast tumors maintained in distant metastases"
		Wright et al., Apr. 1989, *Cancer Res.,* 49:2087-90 "Expression of c-*erbB*-2 Oncoprotein: A Prognostic Indicator in Human Breast Cancer"
		Yang et al., 2002, *Nucleic Acids Res.,* 30(4):e15 "Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation"

23552
PATENT TRADEMARK OFFICE

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.